National Disease Registration Service, NHS England, Quarry House, Quarry Hill, Leeds, LS2 7UE, UK.
Bristol Medical School, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.
Br J Cancer. 2024 Jun;130(10):1697-1708. doi: 10.1038/s41416-024-02645-3. Epub 2024 Mar 18.
Hepatocellular carcinoma (HCC) incidence has increased rapidly, and prognosis remains poor. We aimed to explore predictors of routes to diagnosis (RtD), and outcomes, in HCC cases.
HCC cases diagnosed 2006-2017 were identified from the National Cancer Registration Dataset and linked to Hospital Episode Statistics and the RtD metric. Multivariable logistic regression was used to explore associations between RtD, diagnosis year, 365-day mortality and receipt of potentially curative treatment.
23,555 HCC cases were identified; 36.1% via emergency presentation (EP), 30.2% GP referral (GP), 17.1% outpatient referral, 11.0% two-week wait and 4.6% other/unknown routes. Odds of 365-day mortality was >70% lower via GP or OP routes than EP, and odds of curative treatment 3-4 times higher. Further adjustment for cancer/cirrhosis stage attenuated the associations with curative treatment. People who were older, female, had alcohol-related liver disease, or were more deprived, were at increased risk of an EP. Over time, diagnoses via EP decreased, and via GP increased.
HCC RtD is an important predictor of outcomes. Continuing to reduce EP and increase GP and OP presentations, for example by identifying and regularly monitoring patients at higher risk of HCC, may improve stage at diagnosis and survival.
肝细胞癌 (HCC) 的发病率迅速上升,预后仍然较差。我们旨在探讨 HCC 病例的诊断途径 (RtD) 和预后的预测因素。
从国家癌症登记数据集确定了 2006 年至 2017 年诊断的 HCC 病例,并与医院病例统计数据和 RtD 指标相关联。多变量逻辑回归用于探讨 RtD、诊断年份、365 天死亡率和接受潜在根治性治疗之间的关系。
确定了 23555 例 HCC 病例;36.1% 通过紧急就诊 (EP),30.2% 通过全科医生转诊 (GP),17.1% 通过门诊转诊,11.0% 通过两周等待,4.6% 通过其他/未知途径。与 EP 途径相比,通过 GP 或 OP 途径的 365 天死亡率的可能性降低了>70%,接受根治性治疗的可能性增加了 3-4 倍。进一步调整癌症/肝硬化分期后,与根治性治疗的关联减弱。年龄较大、女性、患有酒精性肝病或更贫困的人 EP 风险增加。随着时间的推移,通过 EP 的诊断减少,而通过 GP 的诊断增加。
HCC 的 RtD 是预后的重要预测因素。继续减少 EP 并增加 GP 和 OP 就诊,例如通过识别和定期监测 HCC 风险较高的患者,可能会改善诊断时的分期和生存。